X4 Pharmaceuticals, Inc.
XFOR
$0.1908
-$0.0045-2.30%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -37.45M | -16.76M | 17.63M | -128.91M | -101.17M |
Total Depreciation and Amortization | 796.00K | 585.00K | 422.00K | 354.00K | 419.00K |
Total Amortization of Deferred Charges | 856.00K | 903.00K | 952.00K | 958.00K | 929.00K |
Total Other Non-Cash Items | -97.78M | -106.50M | -132.78M | 22.19M | 2.96M |
Change in Net Operating Assets | 2.68M | -3.88M | 1.32M | 1.82M | 344.00K |
Cash from Operations | -130.90M | -125.65M | -112.45M | -103.60M | -96.51M |
Capital Expenditure | -326.00K | -320.00K | -236.00K | -110.00K | -60.00K |
Sale of Property, Plant, and Equipment | 105.00M | 105.00M | 105.00M | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -37.68M | -33.90M | -23.21M | -20.09M | -14.82M |
Cash from Investing | 66.99M | 70.78M | 81.55M | -20.20M | -14.88M |
Total Debt Issued | 20.00M | 20.00M | 42.50M | 22.50M | 22.50M |
Total Debt Repaid | -- | 0.00 | -764.00K | -764.00K | -2.06M |
Issuance of Common Stock | 294.00K | 256.00K | 256.00K | 68.99M | 68.99M |
Repurchase of Common Stock | -- | -- | -281.00K | -281.00K | -281.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 0.00 | -250.00K | 193.00K | -631.00K |
Cash from Financing | 20.29M | 20.26M | 41.46M | 90.64M | 88.52M |
Foreign Exchange rate Adjustments | -156.00K | 215.00K | -22.00K | -10.00K | 99.00K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -43.77M | -34.40M | 10.54M | -33.16M | -22.78M |